Presentation of data on rFVIIa in the treatment of bleeding in severely injured trauma patients

The trauma study involved 280 patients in five continents, with critical bleeding related to either blunt or penetrating trauma. Patients that had been hospitalised with life-threatening bleeding, and who had already received transfusion of eight units of blood, were randomised to receive either rFVIIa or placebo, in addition to conventional treatment.

 

The key conclusions from the study were already announced by Novo Nordisk on 19 December 2003. Hence, the presentation will focus on the details regarding patient characteristics, effects on red blood cell transfusion (RBC), reduction in complications and the side effect profile.

 

At 16.30 CET today, corresponding to 15.30 UK time and 10.30 am New York time, a brief conference call subsequent to the actual presentation at the conference will be held. The number of the conference call is +44 207 162 0180 / +1 334 420 4951 and the password is Novo Nordisk. If you have any problem accessing the conference please call Novo Nordisk Investor Relations Coordinator Kazuko Kjeldsen at +45 4442 6035. Investors will also be able to listen in via a link on novonordisk.com, which can be found under 'Investors - Conference call'. Presentation material for the conference call will be made available immediately before the conference on the same page.

 

 

 

 

Novo Nordisk is a healthcare company and a world leader in diabetes care. The company has the broadest diabetes product portfolio in the industry, including the most advanced products within the area of insulin delivery systems. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk employs approximately 18,800 full-time employees in 69 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For more information, visit www.novonordisk.com.

 

 

 

 

For further information please contact: